Browsing by author "Cunningham, David"
Now showing items 21-40 of 80
-
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont, C; Phillips, T; Ghesquieres, H; Cheah, CY; Clausen, MR; et al. (American Society of Clinical Oncology (ASCO), 2022-12-22)PURPOSE: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. Single-agent epcoritamab previously demonstrated ... -
Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
Hewitt, LC; Inam, IZ; Saito, Y; Yoshikawa, T; Quaas, A; et al. (2018-05)Background Oesophageal (OeC) and gastric (GC) cancer patients are treated with similar multimodal therapy and have poor survival. There remains an urgent clinical need to identify biomarkers to individualise patient ... -
Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?
Smyth, EC; Tarazona, N; Peckitt, C; Armstrong, E; Mansukhani, S; et al. (2016-06)Background Strict eligibility criteria are necessary to maintain patient safety and scientific validity in clinical trials. However, this may lead to impaired generalizability of results. As survival in gastrointestinal ... -
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Smyth, EC; Verheij, M; Allum, W; Cunningham, D; Cervantes, A; et al. (2016-09) -
Genomic loss of heterozygosity and survival in the REAL3 trial.
Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; et al. (2018-11-30)Background Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers ... -
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.
Aughton, K; Elander, NO; Evans, A; Jackson, R; Campbell, F; et al. (2021-11-17)Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. Cytidine deaminase ... -
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh, P; Palmer, D; Cicconi, S; Jackson, R; Halloran, CM; et al. (Elsevier BV, 2023-02-01)BACKGROUND: Patients with borderline resectable pancreatic ductal adenocarcinoma have relatively low resection rates and poor survival despite the use of adjuvant chemotherapy. The aim of our study was to establish the ... -
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
Young, K; Hughes, DJ; Cunningham, D; Starling, N (2018-01)Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over 300,000 deaths per year globally there is an ... -
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.
Davidson, M; Chau, I; Cunningham, D; Khabra, K; Iveson, T; et al. (2017-08)Aim To investigate the impact of histology on outcome in advanced oesophageal cancer treated with first-line fluoropyrimidine-based chemotherapy.Methods Individual patient data were pooled from three randomised phase III ... -
In Reply.
Khan, K; Cunningham, D; Aitken, K; Rao, S (2017-11) -
Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma.
Silva, ANS; Saito, Y; Yoshikawa, T; Oshima, T; Hayden, JD; et al.<h4>Background</h4>Patients with Epstein-Barr virus-positive gastric cancers or those with microsatellite instability appear to have a favourable prognosis. However, the prognostic value of the chromosomal status ... -
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.
Faron, M; Cheugoua-Zanetsie, M; Tierney, J; Thirion, P; Nankivell, M; et al. (American Society of Clinical Oncology (ASCO), 2023-07-12)PURPOSE: The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network ... -
The influence of procedural volume on short-term outcomes for robotic pancreatoduodenectomy-a cohort study and a learning curve analysis.
Kawka, M; Gall, TMH; Hand, F; Nazarian, S; Cunningham, D; et al. (SPRINGER, 2023-03-08)BACKGROUND: An increasing number of robotic pancreatoduodenectomies (RPD) are reported, however, questions remain on the number of procedures needed for gaining technical proficiency in RPD. Therefore, we aimed to assess ... -
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
Ramchandren, R; Johnson, P; Ghosh, N; Ruan, J; Ardeshna, KM; et al. (Elsevier BV, 2023-02-01)BACKGROUND: This phase 1b/2 PCYC-1123-CA study evaluated efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab (iR2 regimen) in patients with relapsed/refractory diffuse large B-cell lymphoma ... -
Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.
Crosby, T; Hurt, CN; Falk, S; Gollins, S; Staffurth, J; et al. (2017-03)Background The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and ... -
Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.
Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; et al. (2017-09)This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ... -
A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.
Van Cutsem, E; Karaszewska, B; Kang, Y-K; Chung, HC; Shankaran, V; et al. (AMER ASSOC CANCER RESEARCH, 2019-04-15)PURPOSE: MET gene amplification is associated with poor prognosis in gastric/gastroesophageal junction/esophageal (G/GEJ/E) cancers. We determined antitumor activity, safety, and pharmacokinetics of the small-molecule MET ... -
Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials.
Liu, DHW; Šefčovičová, N; Emmerson, J; Spaans, LN; Saito, Y; et al. (ELSEVIER SCI LTD, 2022-07-01)BACKGROUND: Adenocarcinoma with more than 50% extracellular mucin is a relatively rare histological subtype of gastrointestinal adenocarcinomas. The clinical impact of extracellular mucin in oesophageal adenocarcinoma ... -
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Alderson, D; Cunningham, D; Nankivell, M; Blazeby, JM; Griffin, SM; et al. (2017-09)Background Neoadjuvant chemotherapy before surgery improves survival compared with surgery alone for patients with oesophageal cancer. The OE05 trial assessed whether increasing the duration and intensity of neoadjuvant ... -
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Zinzani, PL; Santoro, A; Gritti, G; Brice, P; Barr, PM; et al. (American Society of Hematology, 2023-09-26)Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor responses to salvage therapy. Nivolumab and brentuximab vedotin (BV) showed promising early efficacy in patients with R/R ...